Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.
Interaction between the extracellular matrix and integrin receptors on cell surfaces leads not only to cell adhesion but also to intracellular signaling events that affect cell migration, proliferation, and survival. The vitronectin receptor alpha(v)beta(3) integrin is of key importance in glioma cell biology. The expression of urokinase-type plasminogen activator receptor (uPAR) was recently shown to co-regulate with the expression of alpha(v)beta(3) integrin. Moreover, restoration of the p16 protein in glioma cells inhibits the alpha(v)beta(3) integrin-mediated spreading of those cells on vitronectin. Thus we hypothesized that adenovirus-mediated down-regulation of uPAR and overexpression of p16 might down-regulate the expression of alpha(v)beta(3) integrin and the integrin-mediated signaling in glioma cells, thereby defeating the malignant phenotype. In this study, we used replication-deficient adenovirus vectors that contain either a uPAR antisense expression cassette (Ad-uPAR) or wild-type p16 cDNA (Ad-p16) and a bicistronic adenovirus construct in which both the uPAR antisense and p16 sense expression cassettes (Ad-uPAR/p16) are inserted in the E1-deleted region of the vector. Infecting the malignant glioma cell line SNB19 with Ad-uPAR, Ad-p16, or Ad-uPAR/p16 in the presence of vitronectin resulted in decreased alpha(v)beta(3) integrin expression and integrin-mediated biological effects, including adhesion, migration, proliferation, and survival Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas.
Adachi
Y
Y
Department of Biomedical Therapeutic Sciences, Division of Cancer Biology, University of Illinois College of Medicine, Peoria, IL 61656, USA.
Lakka
S S
SS
Chandrasekar
N
N
Yanamandra
N
N
Gondi
C S
CS
Mohanam
S
S
Dinh
D H
DH
Olivero
W C
WC
Gujrati
M
M
Tamiya
T
T
Ohmoto
T
T
Kouraklis
G
G
Aggarwal
B
B
Rao
J S
JS
D000256:Adenoviridae / Q000235:genetics*; D017209:Apoptosis; D015153:Blotting, Western; D002455:Cell Division; D002465:Cell Movement; D002469:Cell Separation; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D018076:DNA, Complementary / Q000378:metabolism; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D018014:Gene Transfer Techniques; D005910:Glioma / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D016023:Integrins / Q000378:metabolism*; D008954:Models, Biological; D016254:Mutagenesis, Insertional; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010641:Phenotype; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000235:genetics*; D055293:Receptors, Urokinase Plasminogen Activator; D019030:Receptors, Vitronectin / Q000096:biosynthesis*; D015398:Signal Transduction; D018874:Spheroids, Cellular / Q000378:metabolism; D013997:Time Factors; D014407:Tumor Cells, Cultured; D019096:Vitronectin / Q000378:metabolism
D019941:Cyclin-Dependent Kinase Inhibitor p16; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D016023:Integrins; D016376:Oligonucleotides, Antisense; C524898:PLAUR protein, human; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D019030:Receptors, Vitronectin; D019096:Vitronectin; D019869:Phosphatidylinositol 3-Kinases